Market Cap: $5.56B
MI
Mirum Pharmaceuticals, Inc.
MIRM
NASDAQ (NASDAQ Global Market)USD
Market Cap: $5.56B
Mirum Pharmaceuticals Enhances Workforce with Inducement Awards Amidst Commitment to Rare Disease Treatment Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, a…
Mirum Pharmaceuticals Strengthens Workforce to Enhance Rare Disease Treatment Initiatives Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, takes a significant…
Mirum Pharmaceuticals Sets Ambitious Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., based in Foster City, California, outlines its strategic vision for 2024, forecasting robust growth dr…
Mirum Pharmaceuticals Charts a Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., a California-based biotechnology company, outlines a robust growth strategy for 2024, emphasizing significan…
Mirum Pharmaceuticals Enhances Talent Pool to Drive Rare Disease Treatment Initiatives Mirum Pharmaceuticals, Inc. strengthens its workforce by granting inducement awards to eight new employees, a mov…
Mirum Pharmaceuticals Expands Focus on Rare Diseases with Upcoming Presentation Mirum Pharmaceuticals, Inc. is set to showcase its commitment to addressing rare and orphan diseases at the 43rd Annual…
Mirum Pharmaceuticals Prepares for Key Presentation at J.P. Morgan Healthcare Conference Mirum Pharmaceuticals, Inc., a focused biopharmaceutical company, gears up to present at the 43rd Annual J.P. M…
Mirum Pharmaceuticals Expands Talent Pool with Inducement Awards Amid Focus on Rare Disease Treatments Mirum Pharmaceuticals, Inc. announces the granting of inducement awards to five new employees, a…
Mirum Pharmaceuticals Expands Workforce to Enhance Rare Disease Treatment Efforts Mirum Pharmaceuticals, Inc. highlights its commitment to tackling rare diseases through the recent hiring of seven new…
Mirum Pharmaceuticals Strengthens Commitment to Rare Disease Therapies with Upcoming Conferences Mirum Pharmaceuticals, Inc. is poised to showcase its advancements in rare disease therapies at several…
Mirum Pharmaceuticals Advances Rare Disease Treatment Initiatives Mirum Pharmaceuticals, Inc. is carving a significant niche in the biopharmaceutical landscape, particularly in the realm of rare and o…
Mirum Pharmaceuticals Prepares for Q3 Financial Results and Highlights Rare Disease Developments Mirum Pharmaceuticals, Inc. announces its upcoming third-quarter financial results scheduled for Novemb…
Mirum Pharmaceuticals Gears Up for Q3 Results Amidst Advancements in Rare Disease Treatments Mirum Pharmaceuticals, Inc. is set to release its third quarter 2024 financial results on November 12, 2024…
Mirum Pharmaceuticals Set to Showcase LIVMARLI® Efficacy at NASPGHAN Annual Meeting Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announces its active participation in the upcoming NASPGHAN annual meetin…
Mirum Pharmaceuticals to Showcase LIVMARLI® Data at NASPGHAN Annual Meeting Mirum Pharmaceuticals, Inc. is set to present pivotal clinical data on its FDA-approved treatment LIVMARLI® (maralixibat) du…